SCHEMBL23218328

SCHEMBL23218328

CCOC(=O)Cc1cc(C)ccc1OCc1coc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 7/20 0.45
PLAU P00749 3/20 0.43
PLG P00747 2/20 0.43
F11 P03951 1/20 0.43
KLKB1 P03952 1/20 0.43
F7 P08709 1/20 0.43
TPSB2 P20231 1/20 0.43
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 3/20 0.39
FFAR1 O14842 1/20 0.39
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPK1 P28482 1/20 0.36
PLAT P00750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852877 1.00 CFD (0.45) CFDPLAUPLGF11KLKB1
SCHEMBL23218909 0.93 CFD (0.45) CFDPLAUPLGF11KLKB1
SCHEMBL29852594 0.93 CFD (0.45) CFDPLAUPLGF11KLKB1
SCHEMBL29853207 0.92 CFD (0.46) CFDPLAUPLGF11KLKB1
SCHEMBL23218959 0.92 CFD (0.46) CFDPLAUPLGF11KLKB1
SCHEMBL23218760 0.91 CFD (0.54) CFDPLAUPLGF11KLKB1
SCHEMBL29853224 0.91 CFD (0.54) CFDPLAUPLGF11KLKB1
SCHEMBL23219159 0.91 CFD (0.43) CFDPLAUPLGF11KLKB1
SCHEMBL29852902 0.91 CFD (0.43) CFDPLAUPLGF11KLKB1
SCHEMBL23218614 0.90 CFD (0.54) CFDPLAUPLGF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLAU 1119/4885PLG 421/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLAU 144/4885PLG 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.